Related Experiment Video
Updated: Aug 11, 2026
Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
Published on: April 16, 2019
Oligonucleotide inhibition of Fas as a potential treatment strategy in human liver disease
1GeneTrove, Functional Genomics Division of Isis Pharmaceuticals Inc., Carlsbad, California 92008-7208, USA.
Abstract:
Fas (CD95 or APO-1) is a member of tumor necrosis factor receptor (TNFR) family. Upon activation, by either binding with Fas ligand or self-aggregation, Fas signaling leads to cell apoptosis. Fas is believed to play a role in T-cell- and B-cell-mediated cytotoxicity and depletion; however, Fas is also constitutively expressed in many tissues, including liver. While the function of Fas in normal liver is unclear, many studies have demonstrated that Fas expression in liver is up-regulated under certain inflammatory conditions. A number of clinical reports also indicate that Fas expression and apoptosis are correlated with damage in liver during progression of several hepatic diseases. Therefore Fas may represent an attractive therapeutic target to control excessive or abnormal apoptosis in liver. One approach to regulate Fas expression in vivo is to use antisense oligonucleotides. This class of compound have been shown to be effective inhibitors of gene expression in many organs, including liver, and we have demonstrated protection of liver from apoptotic injury in animals by treatment with antisense oligonucleotides that inhibit Fas. In this article, we describe the evidence of a role for Fas in mediating some forms of liver disease and we review how antisense oligonucleotides can be used to prevent or control this pathology.
Insights
Fas receptor signaling contributes to liver damage and apoptosis in hepatic diseases. Antisense oligonucleotides targeting Fas show promise in protecting the liver from apoptotic injury, offering a potential therapeutic strategy.
Area of Science:
- Immunology
- Hepatology
- Molecular Biology
Background:
- Fas (CD95/APO-1) is a tumor necrosis factor receptor family member.
- Fas activation triggers apoptosis and plays roles in immune cell function.
- Fas is expressed in the liver, with elevated levels during inflammation and correlation with liver disease progression.
Purpose of the Study:
- To investigate the role of Fas in liver disease pathogenesis.
- To explore the therapeutic potential of targeting Fas in liver conditions.
- To review the use of antisense oligonucleotides for modulating Fas expression.
Main Methods:
- Review of existing literature on Fas signaling in liver disease.
- Examination of studies utilizing antisense oligonucleotides to inhibit gene expression in the liver.
- Analysis of animal models demonstrating protection from apoptotic liver injury.
Main Results:
- Fas expression and apoptosis are linked to liver damage in various hepatic diseases.
- Antisense oligonucleotides effectively inhibit gene expression in the liver.
- Treatment with Fas-targeting antisense oligonucleotides protected animal livers from apoptotic injury.
Conclusions:
- Fas is implicated in mediating certain forms of liver disease.
- Antisense oligonucleotides represent a viable approach to control Fas-mediated liver pathology.
- Targeting Fas offers a potential therapeutic strategy for managing liver diseases characterized by excessive apoptosis.
